Literature DB >> 21669462

Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status.

Victoria C Wing1, Ingrid Bacher, Kristi A Sacco, Tony P George.   

Abstract

Schizophrenia is associated with many neurocognitive deficits, some of which are improved by nicotine and cigarette smoking. To better understand the relationship between smoking and cognitive function in schizophrenia, cross-sectional assessment of neuropsychological performance as a function of smoking status (smoker or non-smoker) and smoking history (current, former or never-smoker) in clinically stable outpatients with schizophrenia and controls was evaluated. Subjects (n=140) were divided into subgroups on the basis of self-report and biochemical verification of smoking history. Current smokers with schizophrenia (n=38), former smokers with schizophrenia (n=17), never-smokers with schizophrenia (n=12), control smokers (n=31), control former smokers (n=16), and control never-smokers (n=26) were administered a comprehensive neuropsychological battery. Smokers were studied under non-deprivation conditions. Comparison of neuropsychological performance in schizophrenia and control subjects revealed significant main effects of diagnosis. Analysis of the data as a function of smoking history demonstrated that never-smokers with schizophrenia performed the poorest on measures of sustained attention, processing speed and response inhibition, when compared to the other schizophrenia subgroups. Cigarette smoking did not alter neuropsychological performance in controls. Our findings suggest that smoking status and history differentially alters neuropsychological outcomes in schizophrenia compared to non-psychiatric controls, and that never-smokers may present with more severe neurocognitive impairments. 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21669462      PMCID: PMC5346074          DOI: 10.1016/j.psychres.2011.05.037

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  46 in total

Review 1.  An fMRI study of Stroop word-color interference: evidence for cingulate subregions subserving multiple distributed attentional systems.

Authors:  B S Peterson; P Skudlarski; J C Gatenby; H Zhang; A W Anderson; J C Gore
Journal:  Biol Psychiatry       Date:  1999-05-15       Impact factor: 13.382

Review 2.  Co-morbidity of smoking in patients with psychiatric and substance use disorders.

Authors:  David Kalman; Sandra Baker Morissette; Tony P George
Journal:  Am J Addict       Date:  2005 Mar-Apr

3.  Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia.

Authors:  T P George; D M Ziedonis; A Feingold; W T Pepper; C A Satterburg; J Winkel; B J Rounsaville; T R Kosten
Journal:  Am J Psychiatry       Date:  2000-11       Impact factor: 18.112

4.  A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia.

Authors:  A E Evins; V K Mays; N A Rigotti; T Tisdale; C Cather; D C Goff
Journal:  Nicotine Tob Res       Date:  2001-11       Impact factor: 4.244

5.  The Stroop effect in schizophrenic patients.

Authors:  H H Hepp; S Maier; L Hermle; M Spitzer
Journal:  Schizophr Res       Date:  1996-12-15       Impact factor: 4.939

6.  Neuropsychological deficits in nonsmokers with schizophrenia: effects of a nicotinic antagonist.

Authors:  Kristi A Sacco; Angelo Termine; Melissa M Dudas; Aisha A Seyal; Taryn M Allen; Jennifer C Vessicchio; Bruce E Wexler; Tony P George
Journal:  Schizophr Res       Date:  2006-05-04       Impact factor: 4.939

7.  Nicotine-haloperidol interactions and cognitive performance in schizophrenics.

Authors:  E D Levin; W Wilson; J E Rose; J McEvoy
Journal:  Neuropsychopharmacology       Date:  1996-11       Impact factor: 7.853

8.  Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia.

Authors:  Sara L Dolan; Kristi A Sacco; Angelo Termine; Aisha A Seyal; Melissa M Dudas; Jennifer C Vessicchio; Bruce E Wexler; Tony P George
Journal:  Schizophr Res       Date:  2004-10-01       Impact factor: 4.939

9.  Stages of change in smokers with schizophrenia or schizoaffective disorder and in the general population.

Authors:  Manuela Etter; Sylvia Mohr; Claire Garin; Jean-François Etter
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

10.  Predictors of early abstinence in smokers with schizophrenia.

Authors:  Melissa A Culhane; David A Schoenfeld; Ruth S Barr; Corinne Cather; Thilo Deckersbach; Oliver Freudenreich; Donald C Goff; Nancy A Rigotti; A Eden Evins
Journal:  J Clin Psychiatry       Date:  2008-10-21       Impact factor: 4.384

View more
  15 in total

1.  Nicotine Self-administration Is Not Increased in the Methylazoxymethanol Acetate Rodent Model of Schizophrenia.

Authors:  Jillian J Weeks; Laura E Rupprecht; Anthony A Grace; Eric C Donny; Alan F Sved
Journal:  Nicotine Tob Res       Date:  2020-02-06       Impact factor: 4.244

Review 2.  Heritability of Neuropsychological Measures in Schizophrenia and Nonpsychiatric Populations: A Systematic Review and Meta-analysis.

Authors:  Gabriëlla A M Blokland; Raquelle I Mesholam-Gately; Timothea Toulopoulou; Elisabetta C Del Re; Max Lam; Lynn E DeLisi; Gary Donohoe; James T R Walters; Larry J Seidman; Tracey L Petryshen
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

3.  Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis.

Authors:  Lisa Buchy; Larry J Seidman; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; William Stone; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Daniel H Mathalon; Jean Addington
Journal:  Psychiatry Res       Date:  2015-11-25       Impact factor: 3.222

4.  Comparison of the effectiveness of Conners' CPT and the CPT-identical pairs at distinguishing between smokers and nonsmokers with schizophrenia.

Authors:  Michelle Roth; L Elliot Hong; Robert P McMahon; Rebecca L Fuller
Journal:  Schizophr Res       Date:  2013-06-20       Impact factor: 4.939

5.  Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the "self-medication" hypothesis in schizophrenia.

Authors:  Douglas L Boggs; Toral S Surti; Irina Esterlis; Brian Pittman; Kelly Cosgrove; R Andrew Sewell; Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Schizophr Res       Date:  2017-04-06       Impact factor: 4.939

6.  California Verbal Learning Test-II performance in schizophrenia as a function of ascertainment strategy: comparing the first and second phases of the Consortium on the Genetics of Schizophrenia (COGS).

Authors:  William S Stone; Raquelle I Mesholam-Gately; David L Braff; Monica E Calkins; Robert Freedman; Michael F Green; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Gregory A Light; Keith H Nuechterlein; Ann Olincy; Allen D Radant; Larry J Siever; Jeremy M Silverman; Joyce Sprock; Catherine A Sugar; Neal R Swerdlow; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; Larry J Seidman
Journal:  Schizophr Res       Date:  2014-12-12       Impact factor: 4.939

7.  Lifetime cannabis use and cognition in patients with schizophrenia spectrum disorders and their unaffected siblings.

Authors:  Ana M Sánchez-Torres; Virginia Basterra; Araceli Rosa; Lourdes Fañanás; Amalia Zarzuela; Berta Ibáñez; Víctor Peralta; Manuel J Cuesta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-04-12       Impact factor: 5.270

Review 8.  Neurocognitive endophenotypes in schizophrenia: modulation by nicotinic receptor systems.

Authors:  Kristen M Mackowick; Mera S Barr; Victoria C Wing; Rachel A Rabin; Clairelaine Ouellet-Plamondon; Tony P George
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-07-19       Impact factor: 5.067

Review 9.  nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.

Authors:  Vinay Parikh; Munir Gunes Kutlu; Thomas J Gould
Journal:  Schizophr Res       Date:  2016-01-21       Impact factor: 4.939

10.  Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment.

Authors:  Felice Iasevoli; Raffaele Balletta; Valentina Gilardi; Sara Giordano; Andrea de Bartolomeis
Journal:  Neuropsychiatr Dis Treat       Date:  2013-08-07       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.